Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - A meta-analysis

Nephrology Dialysis Transplantation

Volumn 21, Issue 9, 2006, Pages 2446-2451

  Kielstein, Jan T ^a,c   Salpeter, Shelley R ^a   Bode Boeger, Stefanie M ^b   Cooke, John P ^a   Fliser, Danilo ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Creatinine; Glomerular filtration rate; MDRD fromula; Renal function; SDMA

Indexed keywords

CREATININE; N(G),N(G) DIMETHYLARGININE; ARGININE; BIOLOGICAL MARKER; DIMETHYLARGININE; DRUG DERIVATIVE; INULIN;

ARTICLE; CARDIOVASCULAR RISK; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; HUMAN; INULIN CLEARANCE; KIDNEY FUNCTION; MEDICAL RECORD; MEDLINE; PATIENT CARE; PRIORITY JOURNAL; RELIABILITY; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; MALE; META ANALYSIS; METABOLISM; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CREATININE; FEMALE; HUMANS; INULIN; MALE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33750139969     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl292     Document Type: Article

References (44)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
2. Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilonmono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970; 245: 5751-5758
3. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976; 154: 179-184
4. Cooke JP. Asymmetrical dimethylarginine: The Uber marker? Circulation 2004; 109: 1813-1818
5. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202
6. Fliser D, Kronenberg F, Kielstein JT et al. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461
7. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455
8. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765-769
9. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004; 53: 1574-1579
10. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 2004; 89: 6277-6281
11. Paiva H, Lehtimaki T, Laakso J et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52: 303-307
12. Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest 2005; 35: 32-37
13. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001; 358: 2113-2117
14. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141-151
15. Bode-Boger SM, Scalera F, Kielstein JT et al. Symmetrical dimethylarginine: A new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-1134
16. Nakajima T, Matsuoka Y, Kakimoto Y. Isolation and identification of N-G-monomethyl, N-G, N-G-dimethyl- and N-G,N′ G-dimethylarginine from the hydrolysate of proteins of bovine brain. Biochim Biophys Acta 1971; 230: 212-222
17. McBride AE, Silver PA. State of the arg: Protein methylation at arginine comes of age. Cell 2001; 106: 5-8
18. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
19. Al Banchaabouchi M, Marescau B, Possemiers I, D'Hooge R, Levillain O, De Deyn PP. NG, NG-dimethylarginine and NG, NG-dimethylarginine in renal insufficiency. Pflugers Arch 2000; 439: 524-531
20. Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 2006; 290: H209-H216
21. Pedersen LG, Tarnow I, Olsen LH, Teerlink T, Pedersen HD. Body size, but neither age nor asymptomatic mitral regurgitation, influences plasma concentrations of dimethylarginines in dogs. Res Vet Sci 2006; 80: 336-342
22. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15: 901-909
23. Marescau B, Nagels G, Possemiers I et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997; 46: 1024-1031
24. Kielstein JT, Boger RH, Bode-Boger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176
25. Dalton RN, Booth C, Mallard B, Rigby E, Ridgen S, Turner C. SDMA is an endogenous marker of glomerular filtration rate. J Am Soc Nephrol 2005; 16 (Abstract)
26. Kim KE, Onesti G, Ramirez O, Brest AN, Swartz C. Creatinine clearance in renal disease. A reappraisal. Br Med J 1969; 4: 11-14
27. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38: 167-184
28. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-838
29. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 2002; 40: 221-226
30. Yilmaz MI, Saglam M, Caglar K et al. The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50
31. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997; 1: 65-73
32. Tojo A, Welch WJ, Bremer V et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-1601
33. Nijveldt RJ, Teerlink T, Van Der Hoven B et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: High plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30
34. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003; 349: 1587-1589
35. Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678
36. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006; 184: 383-388. Epub 2005 June 6
37. Nanayakkara PW, Teerlink T, Stehouwer CD et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005; 68: 2230-2236
38. Wanby P, Teerlink T, Brudin L et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006; 185: 271-277
39. Fleck C, Schweitzer F, Karge E, Busch M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 2003; 336: 1-12
40. Ellis J, Wennerholm UB, Bengtsson A et al. Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand 2001; 80: 602-608
41. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 2002; 17: 1999-2002
42. Krzyzanowska K, Mittermayer F, Schnack C, Hofer M, Wolzt M, Schernthaner G. Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest 2005; 35: 208-213
43. Siroen MP, Teerlink T, Bolte AC et al. No compensatory upregulation of placental dimethylarginine dimethylaminohydrolase activity in preeclampsia. Gynecol Obstet Invest 2006; 62: 7-13
44. Lluch P, Mauricio MD, Vila JM et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006; 231: 70-75